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Abstract The goal was to investigate the role of protein kinases 
in modulating taurine transporter activity in Xenopus laevis 
oocytes expressing the mouse retinal Na+lC-Itaurine transpor- 
ter. The currents generated by the taurine transporter were 
studied with a two-electrode voltage clamp and we recorded the 
maximal current (/max), presteady-state charge transfer Q, and 
membrane capacitance Cm. 8-Br-cAMP, a membrane-permeable 
activator of the cAMP-dependent protein kinase (PKA), 
decreased Im~ (41%), Q (41%) and Cm (10%). Similarly, 1 IJM 
sn-l,2-dioctanoylglycerol (DOG), an activator of the Ca2+/ 
diacylglycerolldependent protein kinase (PKC), decreased Imax 
(56%), Q (37%), and Cm (9%). Calyculin A, a specific inhibitor 
of protein phosphatases 1 and 2A, also produced effects similar 
to those of 8-Br-cAMP and DOG, and decreased Imax (64%), Q 
(38%), and Cm (10%). We conclude that the taurine transporter 
is regulated by activators of PKA and PKC, and regulation 
occurs largely by changes in the number of transporters in the 
plasma membrane. 
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1. Introduction 
Taurine (2-aminoethanesulfonic acid) is found in mill imolar 
concentrations in the retina, liver, kidney, heart and brain [1]. 
While many functions have been attr ibuted to taurine, such as 
being an essential nutrient for development of the brain and 
retina, its best understood role is as an osmolyte in the kidney 
and brain [2]. Isoforms of the taurine transporter have been 
sequenced and cloned from dog kidney [3], mouse brain [4], 
mouse retina [5], human placenta [6], and human thyroid [7]. 
They belong to the family of Na +- and C1--dependent co- 
transporters, which include neurotransmitter,  osmolyte and 
amino acid transporters [8]. 
These taurine transporters have one or more putative phos- 
phorylation sites for Ca2+/diacylglycerol-dependent pro ein 
kinase and cAMP-dependent protein kinase [3,4], and there 
is evidence that the kinases are involved in regulation of trans- 
port [9,10]. We have used electrophysiological techniques to 
investigate the role of protein kinases in modulat ing taurine 
transport  in Xenopus laevis oocytes expressing the mouse ret- 
inal taurine transporter. We monitored: (1) the maximal rate 
of Na+/Cl - / taur ine cotransport;  (2) the number  of taurine 
transporters in the plasma membrane [11,12]; and (3) the 
net rate of exo- and endocytosis [13]. 
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2. Materials and methods 
The Na+/Cl-/taurine transporter (TAUT) cloned from mouse reti- 
na [5] was expressed in X. laevis oocytes as described previously [11]. 
The retinal clone was 100% identical to mouse brain taurine trans- 
porter [4]. In a series of experiments in 15 gM taurine, the uptake of 
[3H]taurine in cRNA-injected oocytes (using methods described in 
[14]) was 11 +2 nM/h (n=8), and was 20-fold higher than in non- 
injected oocytes (0.5 + 0.1 nM/h, n = 10), thus confirming that taurine 
is transported into cRNA-injected oocytes. Electrophysiological meas- 
urements were undertaken 5-7 days post-cRNA injection, using a 
two-electrode voltage clamp [11]. During experiments, the oocytes 
were bathed in a standard NaC1 buffer (in mM): 100 NaCI, 2 KC1, 
1 CaCI2, 1 MgC12 and 10 HEPES (pH 7.4). Membrane voltage Vm 
was held at -50 inV. To obtain the steady-state current-voltage rela- 
tions, Vm was stepped for 100 ms from the holding (Vh --50 mV) to 
various test values (lit) between +50 and -150 mV in 20 mV incre- 
ments, and the steady-state currents at 100 ms were measured. The 
currents were digitized at 100 jas/point, and the average current of 
three sweeps was recorded. The steady-state currents generated by 
the taurine transporter (e.g. Fig. 1C) were obtained as the difference 
between the steady-state currents in the presence and absence of tau- 
rine (Fig. 1A,B). Our preliminary kinetic studies indicate the apparent 
affinity constant K0.5 for taurine in 100 mM external NaCI was 15 gM 
[15]. To determine the maximal taurine-induced steady-state current 
I~ ..... a saturating concentration f taurine (500 JaM) was added to the 
bath NaCI buffer. 
Presteady-state currents due to the expression of the taurine trans- 
porter were isolated from the capacitive and leakage currents by fit- 
ting the total current l(t) to: l(t) = I1 e-t/~l + 12e -t/~2 + I~, where 11 is 
the capacitive current with time constant xa, t is time, I2 is the tran- 
sient current due to the taurine transporter with time constant x2, and 
1~ is the steady-state current [11]. Charge movement Q due to the 
taurine transporter was calculated by integrating the presteady-state 
currents at each test voltage Vt. At each test voltage, the ON and 
OFF charges were equal and opposite. Charge-voltage r lations were 
obtained by fitting the charge movement Q (mean of the ON and 
OFF charges) at various test voltages with the Boltzmann equation: 
(Q-Qhyp)lQm~x = ll[l+exp(z(Vt-- Vo.5)FIRT)], in which Q . . . .  = 
Qd~p--Qhyp, Qd~p and Qhyp being Q at depolarizing and hyperpolariz- 
ing limits; T, absolute temperature; F, Faraday's constant; R, gas 
constant; V05, voltage for 50% charge transfer; and z, the apparent 
valence of the movable charge. In kinetic experiments, z was 1, V0.s 
was approx. +50 mV, and Qm~ varied from 9 to 20 nC. The maximal 
charge Qm~ provides a measure of the number of transporters N in 
the plasma membrane (Qm~x=N×exz, where e is the elementary 
charge and z the apparent valence of the movable charge [11,12]). 
Since saturation of the charge vs. voltage relations was not generally 
reached at +50 mV, we used the charge transfer at +50 mV as an 
index of the number of transporters in the plasma membrane. Plasma 
membrane capacitance C~ was determined as the slope of the linear 
charge vs. voltage relations in the presence of 500 jaM external taurine 
[111. 
8-Br-cAMP (8-bromoadenosine Y:5'-cyclic monophosphate) and 
DOG (sn-l,2-dioctanoylglycerol) were used to activate PKA and 
PKC [16,17]. Calyculin A, a specific inhibitor of the protein phospha- 
tases 1 and 2A [18] was also used. Presteady-state and steady-state 
currents were measured in response to external taurine before and 
after incubation (30 min) of the oocytes in NaC1 buffer containing 
these compounds. All components were purchased from Calbiochem 
(San Diego, CA) or Sigma (St. Louis, MO). 
Summarized data are presented as arithmetic mean values _+ S.E.M. 
All rights reserved. 
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Fig. 1. Effect of DOG on steady-state currents. The experiment was performed on an oocyte injected with 50 ng of the mouse retinal taurine 
transporter cRNA. The oocyte was bathed in a NaC1 solution at 20°C. The holding potential (Vh) was -50  mV and test voltages (V0 were ap- 
plied for 100 ms. Shown are the steady-state currents (measured at 100 ms after the onset of the voltage pulse) corresponding to Vt between 
+10 and -150 mV. The taurine-induced steady-state current is the difference in steady-state current in the presence (+) and absence ( - )  of 500 
ktM taurine. (A) Was obtained before, and (B) after incubating the oocyte in 1 ktM DOG for 30 min. (C) Steady-state current-voltage r lation 
of the taurine-induced current before and after DOG treatment. 
with n referring to the number of observations. A paired t-test was 
<:  used to test for statistically significant differences, p _ 0.05 was set as 
significance l vel. 
3. Results 
3.1. PKC activation 
The steady-state currents induced by taurine (500 ~M) in a 
cRNA-injected oocyte before and after exposure to DOG are 
shown in Fig. 1. The taurine-induced current was obtained as 
the difference in current in the presence and absence of taurine 
(Fig. 1A). This current (Fig. 1C, open symbols) was inward, 
increased with hyperpolarizing voltages, and was largest at the 
most negative voltage applied ( -150  mV). After DOG incu- 
bation, the baseline or background current was unaffected 
(open symbols, Fig. 1B), but there was a 60% reduction in 
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Fig. 2. Effect of DOG on presteady-state currents. Shown are the 
current relaxations after membrane voltage was stepped from -50 
mV (Vh) to +50 mV (Vt) for 100 ms before (control) and after incu- 
bating the oocyte in 1 gM DOG. The current consisted of an initial 
capacitive transient with time constant ~= 1.2 ms followed by a 
slower decay (~ = 49 ms) to the steady state. The current relaxations 
were obtained from the total oocyte current by subtraction of the 
background steady-state currents and have been filtered at 300 Hz 
for display. The dashed line indicates the zero current level. The 
presteady-state currrent of the taurine transporter is isolated from 
the current relaxations by subtraction of the capacitive current as 
described in Section 2, and the charge transfer Q is obtained as the 
integral of the presteady-state transients. In this experiment, DOG 
treatment reduced maximum transport rate /max by 54% and Q by 
45%, but there were no differences in the relaxation time constants 
~ON and ZOFF for the presteady-state current: they were 49 + 1 (error 
of the fit) and 19+ 1 ms before, and 49+2 and 19+2 ms, respec- 
tively, after DOG. 
the steady-state current induced by taurine at every membrane 
potential (Fig. 1C, filled symbols). In 5 experiments, the max- 
imal current (at -150  mV) induced by taurine/max before and 
after incubation in DOG was 88_  + 17 and 35_+4 nA, a reduc- 
tion of 56-+ 5% (Fig. 3). 
Fig. 2 shows the current records in response to a step 
change in membrane voltage from the holding potential -50  
to +50 mV in the absence of taurine. The voltage jump elicited 
a capacitive transient which decayed to the steady-state with a 
time constant z = 1 ms, and was followed by a slower decay 
(x-= 50-70 ms) to the steady-state. This slower component  was 
not observed in non-injected oocytes, and was abolished by 
addition of 500 txM taurine (not shown). The presteady-state 
current for both the ON and the OFF  pulses were dramati- 
cally reduced after DOG treatment (Fig. 2). The charge trans- 
fer Q, the integral of the presteady-state current, was reduced 
36 _+ 4% (n = 4). The decrease in taurine transport  due to acti- 
vation of PKC was accompanied by a significant reduction in 
the oocyte membrane capacitance of 9 + 1% from 414 -+ 16 to 
377_+ 19 nF (n=5).  DOG had no effect on the relaxation 
kinetics of the presteady-state currents. In 5 experiments, 
the relaxation time constant XON (for a step jump in mem- 
brane voltage from -50  to +50 mV) was 60-+ 3 ms before, 
and 55 + 3 ms after incubation with DOG;  the time constant 
for the off-response Xorr (the return from +50 to -50  mV) 
was 26 + 3 ms before, and 24 + 2 ms after DOG. 
3.2. PKA activation 
The taurine-induced inward currents were markedly re- 
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Fig. 3. Summary of the inhibition of the taurine transporter by dif- 
ferent effectors of signalling pathways. (A) Inhibitory effect of 0.1 
mM 8-Br-cAMP, 1 gM DOG and 1 gM calyculin A on/max of the 
taurine transporter. (B,C) Similar effects for these three effectors on 
Qmax and Cm, respectively. Data are presented as mean 
values+S.E.M., n=5, except in B, where n=4 for the effect of 
DOG on Q. Paired t-tests were performed on Im~x and Cm before 
and after treatment by the different effectors, and (*) and (**) denote 
p values < 0.02 and 0.004, respectively. There was no significant dif- 
ference between the percentage changes in Q and/max. 
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duced after 8-Br-cAMP incubation (Fig. 3). /max was inhibited 
from 92 + 6 to 55 + 4 nA (n = 5) with a concurrent reduction of 
the presteady-state charge transfer Q by 41 + 8% (n = 5). Simi- 
lar to DOG, the reduction in taurine-induced steady-state 
current was voltage independent, and there was no change 
in the presteady-state kinetics: in 5 experiments XON and 
Tort were 70+4 and 21 +2 ms before, and 70+6 and 24+2 
ms, respectively, after incubation in 8-Br-cAMP. The mem- 
brane capacitance of the oocyte was also reduced significantly 
by 10+ 1% from 398+ 19 to 362+ 17 nF (n=5). 
3.3. Inhibition of prote& phosphatases 1 and 2A by calyculin A 
Calyculin A (1 p.M) also resulted in 64 + 12% inhibition of 
/max, 38 + 5% (n = 5) reduction in Q, and a reduction in the 
membrane capacitance by 10 + 4%. 
In non-injected control oocytes there was no measurable 
TAUT currents and no changes in membrane capacitance 
with short-term incubation of the oocytes in 1 ktM DOG 
(n=3), 0.1 mM 8-Br-cAMP (n=3) or 1 pM calyculin A 
(n = 3). 
4. Discussion 
These electrophysiological experiments demonstrate hat ac- 
tivators of PKA and PKC inhibit taurine transport by the 
cloned retinal Na/C1/taurine transporter expressed in oocytes. 
The maximum rate of taurine transport, as judged by the 
current induced by saturating concentrations of taurine 
(/max), was inhibited 40-60% within 30 min of adding mem- 
brane permeable activators of the kinases. The fact that caly- 
culin A, a potent inhibitor of protein phosphatases 1 and 2A, 
also inhibited taurine transport within the same time scale 
(Fig. 3) strongly suggests that the effects of 8-Br-cAMP and 
DOG are indeed activating the protein kinases. Similar inhib- 
itory effects of PKA and PKC on taurine transport have been 
reported in LLC-PK1, Caco-2 and HT-29 cells, and in astro- 
cytes [10,19-21], but the mechanism is not understood. 
Protein kinase C activation have also been recently shown 
to modulate the activity of other cloned cotransporters ex- 
pressed in oocytes and HEK 293 cells [22-26]. The Na/Pi 
(NaPi-2), Na/Cl/glycine (GLYTlb) cotransporters were inhib- 
ited [23,24] and the Na/CI/GABA (GAT1) cotransporter was 
stimulated after activation of PKC [22]. The modulation of 
the GABA and glycine cotransporters esulted in changes in 
V~×, similar to our observations on the taurine transporter. 
Are protein kinase effects direct or indirect? All the evidence 
indicates indirect effects: (1) removal of the consensus PKC 
phosphorylation sites in GAT1, GLYClb and NaPi-2 by site- 
directed mutagenesis did not eliminate the effects of PKC 
activation [22-24]; (2) cell fractionation experiments indicate 
that PKC modulation caused a redistribution of GAT1 in 
oocytes between cytoplasmic ompartments and the plasma 
membrane [22]; and (3) our charge transfer measurements 
with TAUT1 suggest that the PKA- and PKC-induced reduc- 
tions in the Vm~ are due to a concomitant decrease in the 
number of cotransporters in the plasma membrane. The de- 
crease in the number of plasma membrane transporters (Fig. 
3) was also accompanied by a decrease in the membrane ca- 
pacitance of the oocyte, strongly suggesting that the transpor- 
ters are being internalized by endocytosis. Morphometric 
measurements have validated capacitance measurements as 
indications of the surface area of the oocyte, and changes in 
membrane capacitance as due to exo-and  endocytosis 
[27,281. 
Since activation of PKA and PKC had no effect on the 
presteady-steady kinetics (x), the steady-state current-voltage 
curves of the taurine-induced currents, or the turnover num- 
ber of the taurine transporter (Imax/Qmax [11]), this indicates 
that the kinetics of taurine transport have not been altered. 
Thus, the major effect of the activation of PKA and PKC is 
on the retrieval of the transporters from the plasma mem- 
brane. We cannot preclude a direct effect of protein kinases 
on the taurine transporter and this may account for some of 
the variations observed in the changes in maximum transport 
rate, number of transporters, and the area of the plasma 
membrane (Fig. 3) with PKA and PKC stimulation. 
We conclude that the activity of the cloned retinal taurine 
cotransporter xpressed in oocytes is inhibited by activation of 
protein kinase A and C, and that this occurs by a reduction of 
the number of cotransporters in the plasma membrane. While 
our capacitance measurements indicate that the decrease in 
number of transporters i due to endocytosis, it is not clear 
how the protein kinases regulate this process. The effect of a 
kinase depends on the transporter and the isoform being ex- 
pressed in the oocyte: activation of PKC reduces the number 
of mouse taurine and rabbit glucose cotransporters, but in- 
creases the number of rat GABA and human glucose cotran- 
sporters in the oocyte plasma membrane (Fig. 3 [22,26]); ara- 
chidonic acid reduces the maximal rate of transport by the 
human Na/glutamate transporter (EAAT1) but stimulates 
transport by the human EAAT2 isoform [29]. The action of 
the kinases also depends on the cell type: PKC stimulates the 
rat GABA transporter expressed in oocytes but inhibits it 
HEK 293 cells [22,25]. The physiological significance of the 
differential modulation of cotransporter isoforms by kinases, 
and the dependence of the kinase action on the cell type are 
puzzling. Nevertheless, our results indicate that the kinases 
regulate the taurine transporter by regulating the number of 
transporters in the plasma membrane. 
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